Categories Consumer, Retail, U.S. Markets News
Chinese tourist spending slump pulls down Tiffany holiday sales
US luxury jeweler Tiffany & Co (TIF) cut its yearly profit forecast on Jan. 18 on weaker holiday sales, after spending by Chinese tourists fell unexpectedly on a global level. Tiffany also saw lowering Europe demand.
During the last two months of 2018, worldwide same-store sales fell 2% while net sales slipped 1% — the estimation was that they would increase modestly.
Tiffany Chief Executive Alessandro Bogliolo in a statement said that lower spending by tourists, mostly Chinese, and uncertainties in Europe have adversely affected customer demand.
Alessandro Bogliolo’s statement read, “overall holiday sales results came in short of our expectations.”
In the first part of Friday, Tiffany stock slipped 1% on the news. Till Thursday close, the jeweler saw its stock fall 22% in the past twelve months.
Tiffany also refrained from raising its yearly profit targets in November, possibly due to the same slowdown in spending.
Tiffany is not the only one hit by this latest trend. Underwhelming holiday period results also affected Macy’s (M), Kohls (KSS) and other major US retailers.
On Thursday, another US jeweler Signet (SIG) posted sliding holiday period sales and cut its 2018 profit forecast. Its stock plummeted 20%.
REVISITING THE LAST QUARTER
Back in the last week of November 2018, Tiffany & Co posted a 4% rise in worldwide net sales of $1.01 billion, helped by a 2% improvement in comparable sales for the third quarter. However, the top line then narrowly missed market estimates.
Net earnings for the period fell 5% to $95 million or $0.77 per diluted share. In the Americas, total net sales inched 5% up to $442 million, while Asia-Pacific net sales rose 4% to $294 million.
At October 31, 2018, Tiffany operated 321 stores — 124 in the Americas, 89 in Asia-Pacific, 55 in Japan, 48 in Europe, and five in the UAE — vs. 315 stores a year ago.
Listen to publicly listed companies’ earnings conference calls along with the edited closed caption text
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on